Unlocking Cures for Pediatric Cancer With Artificial Intelligence
Directs the MAHA Commission and the Department of Health and Human Services to harness artificial intelligence to accelerate research into pediatric cancer diagnoses, treatments, and cures, building on the existing Childhood Cancer Data Initiative's data infrastructure.
Establishes a federal coordination effort to expand AI use in clinical trials, data sharing, and interoperability standards — though implementation depends on existing appropriations and future agency action rather than new mandatory funding.
What this order does
What it orders
The order directs the Make America Healthy Again (MAHA) Commission, in coordination with the HHS Secretary, the Assistant to the President for Science and Technology (APST), and the Special Advisor for AI and Crypto, to develop strategies for using AI to improve pediatric cancer diagnostics, treatments, and cures. It focuses federal attention on the Childhood Cancer Data Initiative (CCDI), directing priority funding at NCI-Designated Cancer Centers for data infrastructure improvements, AI-driven analysis of biological data, and better clinical trial design and access. The MAHA Commission is also directed to identify ways to increase investment from existing federal funds and encourage private-sector use of advanced technologies.
The HHS Secretary is separately directed to integrate AI into ongoing health data interoperability work, ensuring electronic health records and claims data can support research and clinical trials, and to finalize interoperability standards for patient data used with AI. The order does not itself create new funding or change any law; all actions are subject to the availability of appropriations and existing legal authorities.
Who it affects
Federal health agencies including HHS, NIH, and OMB, the MAHA Commission, and NCI-Designated Cancer Centers that may receive prioritized research funding. Private-sector healthcare companies and academic researchers are encouraged to develop AI tools. Pediatric cancer patients and their families are the intended ultimate beneficiaries.
Why it matters
Children with cancer and their families could see faster development of AI-powered diagnostics and treatments if agencies follow through. Researchers at NCI-designated centers gain clearer federal priority signals for AI-enabled work, and health data interoperability rules may eventually make it easier to share records for clinical trial recruitment.
What must happen and when
How the order is supposed to work
The MAHA Commission serves as the coordinating hub, working alongside the HHS Secretary, OMB Director, NIH Director, and APST. No binding deadlines are set; agencies are directed to identify and implement strategies, leaving the pace to their discretion. Funding comes from existing appropriations rather than new mandatory spending, limiting near-term enforcement teeth. The HHS Secretary's interoperability standards work is the most concrete deliverable, but no completion date is specified. A general severability clause insulates existing agency authorities from disruption.
Actions and deadlines
- Develop strategies to utilize AI for improved pediatric cancer diagnoses, treatments, cures, and prevention
- Identify and implement strategies to increase investment from existing federal funds for the CCDI and related initiatives
- Encourage private-sector use of advanced technologies, including AI, for pediatric cancer cures
- Integrate AI innovation into interoperability work for electronic health records and claims data
- Finalize interoperability standards for patient data used with AI, covering structured and unstructured data